Search results for "Radio"

showing 10 items of 8895 documents

2021

BackgroundMultiple synergistic combination approaches with cancer drugs are developed to overcome primary resistance to immunotherapy; however, the mechanistic rationale to combine chemoradiotherapy (CRT) with immune checkpoint inhibitors remains elusive.MethodsThis study described the immunological landscape of tumor microenvironment (TME) exposed to CRT. Tumor samples from patients with rectal cancer (n=43) treated with neoadjuvant CRT or radiotherapy were analyzed by nanostring and immunohistochemistry. Studies in mice were performed using three syngeneic tumors (TC1, CT26 and MC38). Tumor-bearing mice were treated either with platinum-based CRT, radiotherapy or chemotherapy. Anti-CTLA-4…

0301 basic medicinePharmacologyCancer ResearchTumor microenvironmentbusiness.industryELISPOTmedicine.medical_treatmentImmunologyImmunotherapyAcquired immune system03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemOncology030220 oncology & carcinogenesismedicineCancer researchMolecular MedicineImmunology and AllergyCytotoxic T cellbusinessCD8ChemoradiotherapyJournal for ImmunoTherapy of Cancer
researchProduct

MicroRNA as crucial regulators of gene expression in estradiol-treated human endothelial cells.

2018

Background/Aims: Estrogen signalling plays an important role in vascular biology as it modulates vasoactive and metabolic pathways in endothelial cells. Growing evidence has also established microRNA (miRNA) as key regulators of endothelial function. Nonetheless, the role of estrogen regulation on miRNA profile in endothelial cells is poorly understood. In this study, we aimed to determine how estrogen modulates miRNA profile in human endothelial cells and to explore the role of the different estrogen receptors (ERα, ERβ and GPER) in the regulation of miRNA expression by estrogen. Methods: We used miRNA microarrays to determine global miRNA expression in human umbilical vein endothelial cel…

0301 basic medicinePhysiologymedicine.drug_classEndothelial cellsCèl·lulesDown-RegulationEstrogen receptorEstrogen receptorsBiologylcsh:PhysiologyEpigenetic regulationReceptors G-Protein-Coupledlcsh:Biochemistry03 medical and health sciencesDownregulation and upregulationmicroRNAGene expressionHuman Umbilical Vein Endothelial CellsmedicineCluster AnalysisHumanslcsh:QD415-436EpigeneticsCells CulturedOligonucleotide Array Sequence AnalysisPrincipal Component AnalysisReceptors d'hormoneslcsh:QP1-981EstradiolGene Expression ProfilingUp-RegulationCell biologyGene expression profilingMicroRNAsMetabolic pathway030104 developmental biologyReceptors EstrogenEstrogenMiRNA
researchProduct

2-Methoxyestradiol and Its Combination with a Natural Compound, Ferulic Acid, Induces Melanoma Cell Death via Downregulation of Hsp60 and Hsp90

2019

Melanoma is an aggressive type of skin cancer with one of the highest mortality rates. Notably, its incidence in the last few decades has increased faster than any other cancer. Therefore, searching for novel anticancer therapies is of great clinical importance. In the present study, we investigated the anticancer potential of 2-methoxyestradiol, potent chemotherapeutic, in the A375 melanoma cellular model. In order to furthermore evaluate the anticancer efficacy of 2-methoxyestradiol, we have additionally combined the treatment with a naturally occurring polyphenol, ferulic acid. The results were obtained using the melanoma A375 cellular model. In the study, we used MTT assay, flow cytomet…

0301 basic medicineProgrammed cell deathArticle Subjectlcsh:RC254-282Ferulic acid03 medical and health scienceschemistry.chemical_compound2-Methoxyestradiol Hsp60 Hsp900302 clinical medicineMedicineMTT assay2-Methoxyestradiolbusiness.industryMelanomaCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCancer cellCancer researchSkin cancerbusinessmedicine.drugResearch Article
researchProduct

Elastin-derived peptide VGVAPG affects the proliferation of mouse cortical astrocytes with the involvement of aryl hydrocarbon receptor (Ahr), peroxi…

2019

Abstract During aging and ischemic and hemorrhagic stroke, elastin molecules are degraded and elastin-derived peptides are released into the brain microenvironment. Val-Gly-Val-Ala-Pro-Gly (VGVAPG) is a repeating hexapeptide in the elastin molecule. It is well documented that the peptide sequence binds with high affinity to elastin-binding protein (EBP) located on the cell surface, thereby transducing a molecular signal into the cell. The aim of our study was to investigate whether EBP, aryl hydrocarbon receptor (Ahr), and peroxisome proliferator-activated receptor gamma (Pparγ) are involved in VGVAPG-stimulated proliferation. Primary astrocytes were maintained in DMEM/F12 medium without ph…

0301 basic medicineProliferationPeroxisome proliferator-activated receptorBiochemistryMice0302 clinical medicinePregnancyImmunology and AllergyRNA Small InterferingReceptorPeptide sequenceCells Culturedchemistry.chemical_classificationEstradiolbiologyChemistryHematologyElastin-derived peptidesCell biologymedicine.anatomical_structure030220 oncology & carcinogenesisFemaleRNA Interferencemedicine.symptomAstrocyteOligopeptidesAstrocyteImmunologyReceptors Cell SurfaceS100 Calcium Binding Protein beta SubunitPparγ03 medical and health sciencesOxazinesmedicineAnimalsMolecular BiologyCell ProliferationAryl hydrocarbon receptorElastinPPAR gammaKi-67 Antigen030104 developmental biologyReceptors Aryl HydrocarbonXanthenesMechanism of actionVGVAPGAstrocytesbiology.proteinElastinFetal bovine serumCytokine
researchProduct

Clinical and Radiographic Assessment of Reasons for Replacement of Metal- Ceramic Fixed Dental Prostheses in Patients Referring to Dental School

2018

Background The expected length of service and reasons for fixed dental prostheses (FDPs) replacement are a frequent inquiry by patients while the answers were mainly based on studies reports that was conducted outside the middle east region. This clinical and radiographic survey was constructed to assess and survey clinically and radiographically the reasons of replacement of metal-ceramic fixed dental prostheses, amongst patients reporting at dental school in Taibah University. Material and methods Between January and May 2016, 151 patients were recruited for this study. Interview (include questions pertained to the length of service of the prosthesis, the nature of complaint as told by pa…

0301 basic medicineProsthetic Dentistrymedicine.diagnostic_testbusiness.industryResearchmedicine.medical_treatmentRadiographyDental prosthesisDentistryPhysical examination030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Metal ceramicProsthesis03 medical and health sciences030104 developmental biology0302 clinical medicineUNESCO::CIENCIAS MÉDICASMedicineLength of serviceIn patientbusinessGeneral DentistryAbutment (dentistry)
researchProduct

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized…

2019

Objectives: Concomitant chemo-radiation is the standard treatment for unresectable stage III non-small cell lung cancer (LA-NSCLC), The aim of this study was to assess the safety and efficacy of oral vinorelbine and cisplatin (OVP) compared with etoposide and cisplatin (EP), both in combination with radiotherapy, in this setting. Material and methods: An open-label, randomized phase II trial was undertaken including 23 hospitals in Spain. Adults with untreated unresectable stage III NSCLC were randomizedl:1 to receive: oral vinorelbine (days 1 and 8 with cisplatin on day 1 in 3-week cycles; 2 cycles of induction, 2 cycles in concomitance) or etoposide (days 1-5 and 29-32 with cisplatin on d…

0301 basic medicinePulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDisease-free survivalmedicine.medical_treatmentNeoplasm metastasisAdministration OralVinorelbine03 medical and health sciences0302 clinical medicineNon-small cell lung cancerInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansProgression-free survivalneoplasmsEtoposideAgedNeoplasm StagingEtoposideCisplatinbusiness.industryStandard treatmentVinorelbineChemoradiotherapyMiddle AgedPhase IIrespiratory tract diseasesRadiation therapySurvival RateClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisConcomitantFemalePatient SafetyCisplatinbusinessClinical trial Disease-free survival Etoposide Neoplasm metastasis Non-small cell lung cancer Phase II Vinorelbinemedicine.drug
researchProduct

Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.

2019

Approximately one third of patients with non-small-cell lung cancer (NSCLC) present with stage III or locally advanced NSCLC. These patients have historically been managed with chemoradiotherapy. However, outcomes for these patients remain poor, with a 5-year survival rate between 15% and 32%. Immune checkpoint inhibitors have revolutionized the treatment of patients with NSCLC. One such agent, durvalumab, a selective high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 binding to programmed cell death protein 1 and cluster of differentiation 80, was recently approved in the consolidation setting after completion of definitive platinum-based c…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyDurvalumabLung Neoplasmsmedicine.medical_treatmentContext (language use)03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansLung cancerSurvival rateImmune Checkpoint InhibitorsPneumonitisbusiness.industryChemoradiotherapyPneumoniamedicine.diseasePrognosisImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessChemoradiotherapyClinical lung cancer
researchProduct

Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and sa…

2020

Abstract Background Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. Methods Data from 56 centres were analysed for adverse events (AE), progression-free survival (PFS), overall survival (OS). Results 126 patients actually received at least 1 cycle durvalumab. Compared to the PACIFIC trial, the EAP population had more advanced stage and included “oligometastatic” stage IV patients and patients with autoimmune disease. PFS (20.1 mont…

0301 basic medicinePulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsDurvalumabPopulationLocally advancednon-small cell lung cancer (NSCLC)03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungInternal medicinemedicineHumanseducationAdverse effecteducation.field_of_studybusiness.industryAntibodies MonoclonalChemoradiotherapyDefinitive chemoradiotherapymedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisExpanded accessbusinessChemoradiotherapyLung Cancer
researchProduct

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

2016

Exclusive chemoradiotherapy (CRT) delivering 50 Gy over 5 weeks with cisplatin and fluorouracil-based chemotherapy is a cornerstone in locally advanced esophageal cancer or non-operable patients since the results of the pivotal study of US Intergroup RTOG-8501 (1). This trial has successfully demonstrated that some patients with esophageal carcinoma may be long-term survivors so that this treatment is now definitely accepted as curative (2). Nevertheless the prognosis is still very disappointing with a 5-year overall survival rate of approximately 25%. Attempts to improve overall survival by escalating the dose of radiotherapy with concurrent cisplatin and fluorouracil has been assessed in …

0301 basic medicinePulmonary and Respiratory MedicineOncologymedicine.medical_specialtymedicine.medical_treatmentLocally advancedCetuximab[SDV.CAN]Life Sciences [q-bio]/CancerOutcomes[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract[ SDV.CAN ] Life Sciences [q-bio]/CancerIntensity-Modulated Radiotherapy03 medical and health sciences0302 clinical medicineInternal medicineCarcinomaMedicineComputingMilieux_MISCELLANEOUSCapecitabineCisplatinChemotherapybusiness.industryCarcinomaInduction ChemotherapyEsophageal cancermedicine.diseaseRadiation-Therapy3. Good healthRadiation therapyEditorial030104 developmental biologyChemoradiationFluorouracil030220 oncology & carcinogenesisIi Randomized-TrialCisplatinbusiness[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractChemoradiotherapymedicine.drug
researchProduct

Regulatory network analysis in estradiol-treated human endothelial cells.

2021

Background/Aims: Estrogen has been reported to have beneficial effects on vascular biology through direct actions on endothelium. Together with transcription factors, miRNAs are the major drivers of gene expression and signaling networks. The objective of this study was to identify a com-prehensive regulatory network (miRNA-transcription factor-downstream genes) that controls the transcriptomic changes observed in endothelial cells exposed to estradiol. Methods: miR-NA/mRNA interactions were assembled using our previous microarray data of human umbilical vein endothelial cells (HUVEC) treated with 17ß- Estradiol (E2) (1 nmol/lL, 24 h). miRNA--mRNA pairings and their associated canonical pat…

0301 basic medicineQH301-705.5FisiologiaBiologyCatalysisArticleInorganic Chemistry03 medical and health sciences0302 clinical medicineGene expressionCadherin bindingHuman Umbilical Vein Endothelial CellsHumansGene Regulatory NetworksRNA MessengerPhysical and Theoretical ChemistryBiology (General)Molecular BiologyTranscription factorQD1-999Spectroscopytranscription factormiRNAEstradiolMicroarray analysis techniquesOrganic ChemistryPromoterEstrogensGeneral Medicineendothelial cellsComputer Science ApplicationsCell biologyDNA binding siteChemistryMicroRNAs030104 developmental biology030220 oncology & carcinogenesisCell adhesion molecule bindingTRANSFACTranscriptome
researchProduct